Please use this identifier to cite or link to this item:
|Title:||The role of immunotherapy in Guillain-Barré syndrome: Understanding the mechanism of action|
|Keywords:||acute autoimmune neuropathies|
|Citation:||Shahrizaila, N., Yuki, N. (2011-07). The role of immunotherapy in Guillain-Barré syndrome: Understanding the mechanism of action. Expert Opinion on Pharmacotherapy 12 (10) : 1551-1560. ScholarBank@NUS Repository. https://doi.org/10.1517/14656566.2011.564160|
|Abstract:||Introduction: Guillain-Barré syndrome (GBS) is the most frequent cause of acute flaccid paralysis and, despite treatment, there continues to be an associated mortality and severe disability ranging from 9 to 17%. This article reviews the rationale behind the existing immunotherapy in GBS and discusses the future direction that work in this area should follow. Areas covered: The pathogenesis of GBS and the current evidence for the different forms of immunotherapy in GBS are reviewed. The proposed mechanism of action of each treatment (steroids, plasma exchange and intravenous immunoglobulin (IVIG)) in GBS are discussed. Expert opinion: Both plasma exchange and IVIG are equally effective in GBS although the latter is preferred in view of its ease of access and lower rates of complications. Although not clinically established, there may be a role for the concomitant use of steroids with IVIG and, in patients with severe disease and poor prognostic scores, plasma exchange followed by IVIG or two successive IVIG may prove beneficial. © Informa UK, Ltd.|
|Source Title:||Expert Opinion on Pharmacotherapy|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 19, 2019
WEB OF SCIENCETM
checked on Nov 21, 2017
checked on Jan 11, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.